[Form 4] CITIGROUP INC Insider Trading Activity
Rhea-AI Filing Summary
This Form 4 discloses insider activity by Duncan P. Hennes, a Director of Citigroup Inc. (C). On 10/01/2025 the reporting person acquired 12.5934 shares and 213.9331 shares of Citigroup common stock at a reported price of $102.368 per share. The filings identify the smaller amount as a reinvestment of dividend equivalents under the company's compensation plan for non-employee directors and the larger amount as deferred shares held for the reporting person under the same plan.
The form is signed by an attorney-in-fact on behalf of Mr. Hennes and reports the holdings as a mix of direct and indirect beneficial ownership: the reinvested dividend shares are direct, while the deferred shares are indirect. No derivative transactions or other dispositions are reported on this Form 4.
Positive
- Director acquisition disclosed for transparency with exact share amounts (12.5934 and 213.9331)
- Transactions tied to compensation plan, described as dividend reinvestment and deferred shares, clarifying the nature of the holdings
- Form signed by attorney-in-fact on 10/03/2025, meeting filing formalities
Negative
- None.
Insights
Director received small equity via compensation plan; holdings split direct and indirect.
The filing shows a director-acquisition event on 10/01/2025 totaling 226.5265 shares (sum of 12.5934 and 213.9331), recorded at $102.368 per share. The transaction types are explicitly described as dividend reinvestment and deferred share holdings under the issuer's non-employee director compensation plan.
This matters for governance transparency because it updates insider ownership levels and clarifies the form of director compensation; both direct and indirect holdings are disclosed as required under Section 16.
Form 4 correctly reports Section 16 transactions and includes explanatory footnotes.
The filing lists transaction codes and identifies the nature of beneficial ownership with footnotes: reinvestment of dividend equivalents and deferred shares held for benefit. The form is signed by an attorney-in-fact on 10/03/2025, satisfying signature requirements.
For investors and regulators, this provides the concrete record required by the Exchange Act; there are no amendments or derivative positions disclosed on this form.